Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 15Cisplatin 15pembrolizumab 9Oxaliplatin 7durvalumab 5Leucovorin 5Fluorouracil 5130-nm albumin-bound paclitaxel 5Platinum 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4Trastuzumab 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Capecitabine 3Biopsy 3zanidatamab 2fludarabine 2Paclitaxel 2Nivolumab 2Folfox protocol 2Docetaxel 2Cyclophosphamide 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1pertuzumab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × guadecitabine × 1 year × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡